Skip to main content

Table 3 Cell viability (%) of HLECs after treatment with gigantol, syringic acid, and the combination in the presence of high glucose

From: Investigation of synergistic mechanism and identification of interaction site of aldose reductase with the combination of gigantol and syringic acid for prevention of diabetic cataract

gigantol (μg/mL) syringic acid (μg/mL)
0 0.125 0.625 1.25 2.5
0 28.23 ± 1.12* 32.62 ± 1.56 36.21 ± 2.18 41.52 ± 1.53 47.72 ± 1.49
0.1 35.33 ± 1.87 68.02 ± 1.27 69.01 ± 1.79 71.09 ± 1.94 73.99 ± 1.35
0.5 39.55 ± 1.25 69.77 ± 2.22 75.05 ± 2.15 76.26 ± 1.28 78.96 ± 1.57
1 44.71 ± 2.51 71.16 ± 1.61 73.66 ± 1.24 82.51 ± 1.53 83.02 ± 1.82
2 50.65 ± 1.47 72.76 ± 1.59 74.13 ± 1.27 83.43 ± 1.56 89.16 ± 1.32
  1. Cells were incubated with various concentrations of gigantol, SA and their combination in presence of high glucose (50 mM, containing medium) for 72 h. The cell viability of normal group (5.56 mM glucose), osmolarity control group and model group were 100 ± 0.89 %, 98.33 ± 0.24 % and 28.23 ± 1.12 %, respectively. Cells were treated for 72 h, respectively. independent experiments. Data were expressed as mean ± SD (n = 3), * P < 0.01 vs all other groups